Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| FDA EUA | Other Identifier | FDA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CytoSorbents Europe GmbH | INDUSTRY |
Not provided
Not provided
The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 ICU Patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CytoSorb 300 mL device | Device | CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. |
|
| Measure | Description | Time Frame |
|---|---|---|
| ICU mortality | From the date of start of CytoSorb use until the date of ICU discharge or date of death, whichever comes first, assessed up to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of ECMO after start of CytoSorb | From the date of start of CytoSorb use until the date of cessation of ECMO or date of death, which ever comes first, assessed up to 1 year | |
| Duration of mechanical ventilatory support after start of CytoSorb | From the date of start of CytoSorb use until the date of cessation of mechanical ventilatory support or date of death, which ever comes first, assessed up to 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
COVID-19 ICU patients receiving CytoSorb hemoadsorption via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Peter Nelson, MD | CytoSorbents Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Center of Aurora | Aurora | Colorado | 80012 | United States | ||
| University of Chicago Medicine |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37337243 | Derived | Hayanga JWA, Song T, Durham L, Garrison L, Smith D, Molnar Z, Scheier J, Deliargyris EN, Moazami N. Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Crit Care. 2023 Jun 19;27(1):243. doi: 10.1186/s13054-023-04517-3. | |
| 34988092 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Duration of pharmacologic hemodynamic support after start of CytoSorb | From the date of start of CytoSorb use until the date of cessation of pharmacologic hemodynamic support or date of death, which ever comes first, assessed up to 1 year |
| Change in serum concentrations of inflammatory biomarkers after start of CytoSorb | From the day before start of CytoSorb use until the day after cessation of CytoSorb use |
| Change in Pa02/Fi02 ratio after start of CytoSorb | From the day before start of CytoSorb use until the day after cessation of CytoSorb use |
| Chicago |
| Illinois |
| 60637 |
| United States |
| Franciscan Health Indianapolis | Indianapolis | Indiana | 46237 | United States |
| Baptist Memorial Hospital | Southaven | Mississippi | 38671 | United States |
| New York University Medical Center | New York | New York | 10016 | United States |
| West Virginia University | Morgantown | West Virginia | 26506 | United States |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |
| Song T, Hayanga J, Durham L, Garrison L, McCarthy P, Barksdale A, Smith D, Bartlett R, Jaros M, Nelson P, Molnar Z, Deliargyris E, Moazami N. CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry. Front Med (Lausanne). 2021 Dec 20;8:773461. doi: 10.3389/fmed.2021.773461. eCollection 2021. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |